Incyte Corporation vs Standard Lithium Ltd — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Standard Lithium Ltd trades at $2.27 (market cap $523.89M). The key difference: Incyte Corporation is far larger — about 44.1× Standard Lithium Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | SLI | |
|---|---|---|
Market Cap | $23.11B | $523.89M |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $5.65 |
52-Week Low | $67.38 | $2.15 |
Enterprise Value | $19.13B | $383.09M |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →